MRCCC Siloam takes home win at Healthcare Asia Awards 2025

It has employed a multidisciplinary team model that integrates several areas of medicine for a patient-centred approach.

Mochtar Riady Comprehensive Cancer Centre (MRCCC) Siloam Hospital was honoured as the Specialty Hospital of the Year (Oncology) - Indonesia during the highly sought-after Healthcare Asia Awards 2025 for its achievements in redefining cancer care in the country through advanced technology and multidisciplinary collaboration.

MRCCC Siloam offers a full spectrum of cancer treatments, supported by an advanced infrastructure that includes multiple linear accelerators and brachytherapy for radiotherapy, PET and SPECT scanners, an in-house cyclotron, and therapies such as Lu-PSMA and thyroid ablation.

With the capacity for bone marrow transplant and other complex procedures, it provides some of the country's most sophisticated cancer treatment capabilities, enabling precise and comprehensive care.

Beyond technology, the hospital’s commitment to high-quality care is exemplified by its multidisciplinary team (MDT) model, which integrates medical oncology, surgical oncology, radiation oncology, radiology, pathology, nuclear medicine, and other related specialties for a patient-centred approach.

Implementing MDTs is particularly challenging in Indonesia due to the limited number of oncologists and varying willingness amongst doctors to engage in MDT collaboration. Despite these obstacles, MRCCC's success underscores the commitment of its leadership and medical team to delivering coordinated, effective care to every patient.

The MDT model has produced remarkable clinical achievements, inspiring trust and loyalty amongst patients.

For instance, MRCCC has achieved a 100% cancer-free margin rate in breast-conserving surgeries, reflecting high precision and minimised recurrence risk. Its re-laparotomy rate for gastrointestinal cancer is also below 2%, surpassing the global benchmark of 10%, whilst for lung cancer, 100% of e-GFR test results are available within five days.

In gynaecologic oncology, 87% of complex cases start treatment within two weeks, and the one-year survival rate for acute myeloid leukemia post-chemotherapy reaches an impressive 93%. These results showcase MDT's impact on both patient satisfaction and clinical success.

“In conclusion, MRCCC exemplifies the future of cancer care by blending advanced technology with a robust MDT framework and community-centred initiatives. By setting new standards in oncology, MRCCC remains dedicated to excellence, innovation, and compassionate patient care, establishing itself as a leader in comprehensive cancer treatment in Indonesia,” the company said.

Healthcare Asia Awards honours exceptional hospitals across the region that have redefined the standards of excellence in the industry through their innovative solutions and substantial contributions to communities.

The Healthcare Asia Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2026 awards programme and be acclaimed for your organisation's remarkable initiatives and contributions to the healthcare industry, please contact Julie Anne Nuñez at [email protected].